Bristol Myers Squibb says ZENBEXUS combo cuts multiple myeloma progression risk 51% in Phase 3 EXCALIBER-RRMM trial

• Bristol Myers Squibb reported positive topline Phase 3 EXCALIBER-RRMM results for ZENBEXUS with daratumumab and dexamethasone in relapsed multiple myeloma.
• The regimen extended the time patients lived without disease worsening versus a standard-of-care comparator, supporting a stronger competitive profile.
• Detailed data are scheduled for presentation at the American Society of Hematology annual meeting; earlier response findings were presented at the International Myeloma Society meeting.
• ZENBEXUS has accelerated US clearance in this setting, with continued marketing dependent on confirmatory clinical benefit from trials such as EXCALIBER-RRMM.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 202610080659BIZWIRE_USPR_____20261007_BW805859) on October 08, 2026, and is solely responsible for the information contained therein.